Chapter 36
Hepatitis in Persons Infected with HIV
Janice Main,
Brendan McCarron,
Janice Main
Department of Medicine, Imperial College London, St Mary's Hospital Campus, London, UK
Search for more papers by this authorBrendan McCarron
South Tees Hospitals NHS Foundation Trust, Middlesborough, UK
Search for more papers by this authorJanice Main,
Brendan McCarron,
Janice Main
Department of Medicine, Imperial College London, St Mary's Hospital Campus, London, UK
Search for more papers by this authorBrendan McCarron
South Tees Hospitals NHS Foundation Trust, Middlesborough, UK
Search for more papers by this authorBook Editor(s):Howard C. Thomas BSc, PhD, FRCP, FRCPath, FMedSci,
Anna S.F. Lok MD,
Stephen A. Locarnini MBBS, BSc(Hons), PhD, FRCPath,
Arie J. Zuckerman MD, DSc, FRCP, FRCPath, FMedSci,
Howard C. Thomas BSc, PhD, FRCP, FRCPath, FMedSci
Emeritus Professor of Hepatology, Department of Medicine, Imperial College London, London, UK
Search for more papers by this authorAnna S.F. Lok MD
Alice Lohrman Andrews Research Professor in Hepatology, Director of Clinical Hepatology, Professor of Internal Medicine, Associate Chair for Clinical Research, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, MI, USA
Search for more papers by this authorStephen A. Locarnini MBBS, BSc(Hons), PhD, FRCPath
Head, Research & Molecular Development, Victorian Infectious Diseases Reference Laboratory, Melbourne, VIC, Australia
Search for more papers by this authorArie J. Zuckerman MD, DSc, FRCP, FRCPath, FMedSci
Emeritus Professor of Medical Microbiology, Formerly Principal and Dean, Royal Free Hospital School of Medicine
Search for more papers by this authorFirst published: 26 July 2013
Summary
With shared routes of transmission, viral hepatitis is very common in patients with HIV infection. The increase in liver-related mortality is causing concern. It is important therefore to screen individuals infected with HIV for viral hepatitis and to consider antiviral therapy. For patients with HIV and chronic hepatitis B virus (HBV) infection, an antiretroviral regimen with activity against HBV is recommended. Pegylated interferon and ribavirin therapy has reduced efficacy in HIV-positive patients with chronic hepatitis C virus (HCV) infection, and it is hoped that the newer directly antiviral agents, despite potentially challenging drug interactions, will improve the success rate in this group.
References
- Hess G, Clemens R, Bienzle U, et al. Immunogenicity and safety of an inactivated hepatitis A vaccine in anti-HIV positive and negative homosexual men. J Med Virol 1995; 46: 40–42.
- Weber R, Sabin CA, Friis Moller N, et al. Liver related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006; 166: 1632–1641.
- Konopnicki D, de Mocroft A, Wit S, et al. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS 2005; 19: 593–601.
- Firnhaber C, Reyneke A, Schulze D, et al. The prevalence of hepatitis B co-infection in a South African urban government HIV clinic. South African Med J 2008; 98: 541–544.
- Noonan C, Yoffe B, Mansell P, et al. Extrachromosomal sequences of hepatitis B virus DNA in peripheral blood mononuclear cells of acquired immune deficiency syndrome patients. Proc Natl Acad Sci USA 1986; 83: 5698–5702.
- Poli G, Kinter AL, Justement JS, et al. Tumor necrosis factor α functions in an autocrine manner in the induction of HIV expression. Proc Natl Acad Sci USA 1990; 87: 782–785.
- Seto E, Yen T, Peterlin B, Ou J-H. Transactivation of the human immunodeficiency virus long terminal repeat by the hepatitis B virus X protein. Proc Natl Acad Sci USA 1988; 85: 8286–8290.
- Twu JS, Robinson WS. Hepatitis B virus X gene can transactivate heterologous viral sequences. Proc Natl Acad Sci USA 1989; 86: 2046–2050.
- Hadler SC, Judson FN, O'Malley PM, et al. Outcome of hepatitis B virus infection in homosexual men and its relation to prior human immunodeficiency virus infection. J Infect Dis 1991; 163: 454–459.
- Goldin RD, Fish DE, Hay A, et al. Histological and immunohistochemical study of hepatitis B virus in human immunodeficiency virus infection. J Clin Pathol 1990; 43: 203–205.
- Fang JW, Wright TL, Lau JY. Fibrosing cholestatic hepatitis in patient with HIV and hepatitis B. Lancet 1993; 342: 1175.
- Thio C, Seaberg E, Skolasky R. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter AIDS Cohort Study (MACS). Lancet 2002; 360: 1921–1926.
- Puoti M, Cozzi-Lepri A, Paraninfo G, et al. Impact of lamivudine on the risk of liver-related death in 2,041 HBsAg- and HIV-positive individuals: results from an inter-cohort analysis. Antivir Ther 2006; 11: 567–574.
- Ingiliz P, Valantin MA, Thibault V, et al. Efficacy and safety of adefovir dipivoxil plus pegylatedinterferon-alpha2a for the treatment of lamivudine-resistant hepatitis B virus infection in HIV-infected patients. Antivir Ther 2008; 13: 895–900.
- Gazzard B, Anderson A, Babiker A, et al. British HIV Association guidelines for the treatment of HIV-1 infected adults with antiretroviral therapy 2008. HIV Med 2008; 9: 563–608.
- McMahon MA, Jilek BL, Brennan TP, et al. The HBV drug entecavir – effects on HIV-1 replication and resistance. N Engl J Med 2007; 356: 2614–2621.
- Carr A, Cooper DA. Restoration of immunity to chronic hepatitis B infection in HIV-infected patient on protease inhibitor. Lancet 1997; 349: 995–996.
- Vibert E, Adam R, Tralhao J, Azoulay D, Castaing D, Samuel D. Evolution after listing and results of liver transplantation for hepatocellular carcinoma in HIV/HCV and HIV/HBV coinfected patients. Liver Transp 2008; 14: S220–S221.
- Carne CA, Weller IV, Waite J, et al. Impaired responsiveness of homosexual men with HIV antibodies to plasma derived hepatitis B vaccine. BMJ 1987; 294: 866–868.
- Laukamm-Josten U, Muller O, Benzie U, et al. Decline of naturally acquired antibodies to hepatitis B surface antigen in HIV-1 infected homosexual men with AIDS. AIDS 1988; 2: 400–401.
- van de Laar TJ, Matthews GV, et al. Acute hepatitis C inHIV-infected men who have sex with men: an emerging sexually transmitted infection. AIDS 2010; 24: 1799–1812.
- Thomson EC, Nastouli E, Main J, et al. Delayed anti-HCV antibody response in HIV-positive men acutely infected with HCV. AIDS 2009; 23: 89–93.
- Danta M, Brown D, Bhagani S, et al. HIV and Acute HCV (HAAC) group. Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours. AIDS 2007; 21: 983–991.
- Thomson EC, Fleming VM, Main J, et al. Predicting spontaneous clearance of acute hepatitis C virus in a large cohort of HIV-1-infected men. Gut 2011; 60: 837–845.
- Martin-Carbonero L, Sanchez-Somolinos M, et al. Reduction in liver-related hospital admissions and deaths in HIV-infected patients since the year 2002. J Viral Hepat 2006; 13: 851–857.
- Salmon-Ceron D, Lewden C, Morlat P, et al. Mortality 2000 study group. Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol. J Hepatol 2005; 42: 799–805.
- Salmon-Ceron D, Rosenthal E, Lewden C, et al. Emerging role of hepatocellular carcinoma among liver-related causes of deaths in HIV-infected patients: the French national Mortalite 2005 study. J Hepatol 2009; 50: 736–745.
- Benhamou Y, Bochet M, Di Martino V, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 1999; 30: 1054–1058.
- Qurishi N, Kreuzberg C, Lüchters G, et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet 2003; 362: 1708–1713.
- Sherman KE, Andersen JW, Butt AA, et al. Sustained long-term antiviral maintenance therapy in HCV/HIV-coinfected patients (SLAM-C). J AIDS 2010; 55: 597–605.
- Rohrbach J, Robinson N, Harcourt G, et al. Cellular immune responses to HCV core increase and HCV RNA levels decrease during successful antiretroviral therapy. Gut 2010; 59: 1252–1258.
- Greub G, Ledergerber B, Battegay M, et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet 2000; 356: 1800–1805.
- Gilleece YC, Browne RE, Asboe D, et al. Transmission of hepatitis C virus among HIV-positive homosexual men and response to a 24-week course of pegylated interferon and ribavirin. J AIDS 2005; 40: 41–46.
- Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351: 438–450.
- Mauss S, Valenti W, DePamphilis J, et al. Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during interferon-based therapy. AIDS 2004; 18: F21–F25.
- Vispo E, Barreiro P, Pineda JA, et al. Low response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavir. Antivir Ther 2008; 13: 429–437.
- Seden K, Back D. Directly acting antivirals for hepatitis C and antiretrovirals: potential for drug-drug interactions. Curr Opin HIV AIDS 2011; 6: 514–526.
- Carrat F, Bani-Sadr F, Pol S, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004; 292: 2839–2848.
- Rodriguez-Torres M, Slim J, Bhatti L, et al. Standard versus high dose ribavirin in combination with peginterferon alfa-2a (40KD) in genotype 1 (G1) HCV patients coinfected with HIV: final results of the PARADIGM study. AASLD 2009.
- Laguno M, Cifuentes C, Murillas J, et al. Randomized trial comparing pegylated interferon alpha-2b versus pegylated interferon alpha-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients. Hepatology 2009; 49: 22–31.
- Núñez M, Miralles C, Berdún MA, et al. Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial. AIDS Res Hum Retroviruses 2007; 23: 972–982.
- Rallón NI, Soriano V, Naggie S, et al. IL28B gene polymorphisms and viral kinetics in HIV/hepatitis C virus-coinfected patients treated with pegylated interferon and ribavirin. AIDS 2011; 25: 1025–1033.
- Dieterich D, Soriano V, Sherman K, et al. Telaprevir in combination with pegylated interferon-alfa-2a + ribavirin in HCV/HIV-coinfected patients: a 24-week treatment interim analysis. Paper presented at the 19th Conference on Retroviruses and Opportunistic Infections (CROI 2012), Seattle, WA, March 5–8, 2012.
- Sulkowski M, Pol S, Cooper C, et al. Boceprevir + pegylated interferon + ribavirin for the treatment of HCV/HIV-coinfected patients: end of treatment (week 48) interim results. PEG-IFN and placebo 19th Conference on Retroviruses and Opportunistic Infections (CROI 2012), Seattle, WA, March 5–8, 2012.
- Terrault NA, Roland ME, Schiano T, et al. Outcomes of liver transplantation in HCV-HIV coinfected recipients. Liver Transpl 2012 doi:10.1002/lt.23411 [Epub ahead of print].
- Dalton HR, Bendall RP, Keane FE, et al. Persistent carriage of hepatitis E virus in patients with HIV infection. N Engl J Med 2009; 361: 1025–1027.
- Tillmann HL, Heiken H, Knapik-Botor A, et al. Infection with GB virus C and reduced mortality among HIV-infected patients. N Engl J Med 2001; 345: 715–724.
